Positron emission tomography imaging as a key enabling technology in drug development.
The use of positron emission tomography (PET) in drug development has become more common in the pharmaceutical industry in recent years. One of the biggest challenges to gaining acceptance of this technology is for project teams to understand when to use PET. This chapter reviews the usage of PET in drug development in the context of target, mechanism and efficacy biomarkers. Examples are drawn from a number of therapeutic areas, but we also show that the relative penetration of this technology beyond CNS and oncology applications has been relatively small. However, with the increasing availability of PET and development of novel radiotracers it is expected that the utilization will be much broader in future years, with the additional expectation that the use of PET as an efficacy biomarker will also become more evident.
McCarthy
T J
TJ
Pfizer Global Research and Development, Mystic, CT 06355, USA. timothy.j.mccarthy@pfizer.com
D000818:Animals; D015415:Biomarkers / Q000737:chemistry; D015195:Drug Design; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*
D015415:Biomarkers